Literature DB >> 2142447

Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.

D R Abernethy1, J Gutkowska, L M Winterbottom.   

Abstract

Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension. Elderly (mean +/- SD; age, 68 +/- 3 years) and young (35 +/- 5 years) patients received single intravenous amlodipine doses followed by oral administration once daily for a total of 12 weeks. After intravenous administration, elderly patients had prolonged elimination half-life values (58 +/- 11 versus 42 +/- 8 hours; p less than 0.01) caused by decreased clearance (19 +/- 5 versus 25 +/- 7 L/hr; p less than 0.01). After a 3-months oral treatment washout period, half-life tended to be prolonged in the elderly patients (69 +/- 20 hours for the elderly patients versus 53 +/- 14 hours for the young patients; difference not significant) and was not markedly different from the short-term intravenous measurement. Both systolic and diastolic blood pressure were significantly decreased from baseline throughout the treatment period, with greater decreases in elderly patients for both systolic and diastolic pressure. When amlodipine plasma concentration was correlated to change in mean blood pressure after short-term intravenous doses, elderly patients had a greater decrease than young patients at a given drug concentration. However, after long-term oral administration, elderly and young patients had comparable decreases in mean blood pressure at a given drug concentration, and the increased antihypertensive effect in the elderly was associated with somewhat higher amlodipine plasma concentration. Amlodipine administered once daily is an effective antihypertensive agent in elderly patients and young patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142447     DOI: 10.1038/clpt.1990.120

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  Drug selection for optimal treatment of hypertension in the elderly.

Authors:  E Shammas; K Dickstein
Journal:  Drugs Aging       Date:  1997-07       Impact factor: 3.923

Review 2.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 3.  Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists.

Authors:  R Donnelly; H L Elliott; P A Meredith
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

Review 4.  Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.

Authors:  D Murdoch; R C Heel
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

Review 5.  Role of a third generation calcium antagonist in the management of hypertension.

Authors:  M Epstein
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 6.  Drug dosage in the elderly. Is it rational?

Authors:  K Turnheim
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

Review 7.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 8.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

Review 9.  Clinical pharmacokinetics of amlodipine.

Authors:  P A Meredith; H L Elliott
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

Review 10.  Report of the Canadian Hypertension Society Consensus Conference: 4. Hypertension in the elderly.

Authors:  R A Reeves; J G Fodor; C I Gryfe; C Patterson; J D Spence
Journal:  CMAJ       Date:  1993-09-15       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.